Evidence map›Paper›PMID 41405200›Full record

ArticlemSystems2025

Model-informed development of bacteriophage therapy: bridging

Jun Seok Cha, Kyungnam Kim, Hwa Jeong You, Dasom Kim, Hyun Hee Park, SuJin Heo, Choon Ok Kim, Byung Hak Jin, Dongeun Yong, Dongwoo Chae

Abstract read
In one paragraph

Article in mSystems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jun Seok ChaDepartment of Pharmacology, Yonsei University, Seodaemun-gu, Seoul, Republic of Korea.ORCID 0009-0006-2894-5323
Kyungnam KimMicrobiotix Co., Ltd, Seoul, Republic of Korea.
Hwa Jeong YouMicrobiotix Co., Ltd, Seoul, Republic of Korea.
Dasom KimMicrobiotix Co., Ltd, Seoul, Republic of Korea.
Hyun Hee ParkMicrobiotix Co., Ltd, Seoul, Republic of Korea.
SuJin HeoMicrobiotix Co., Ltd, Seoul, Republic of Korea.
Choon Ok KimDepartment of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
Byung Hak JinDepartment of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
Dongeun Yong *Microbiotix Co., Ltd, Seoul, Republic of Korea.ORCID 0000-0002-1225-8477
Dongwoo Chae *Department of Pharmacology, Yonsei University, Seodaemun-gu, Seoul, Republic of Korea.ORCID 0000-0002-7675-3821

Funding

Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of KoreaKorea Health Industry Development Institute HI23C121600Korea Health Industry Development Institute P0023226
6 · The paper itself

Abstract

Bacteriophages are emerging as promising alternatives to antibiotics for multidrug-resistant (MDR) infections. However, their unique pharmacokinetic and pharmacodynamic (PKPD) properties arising from host-dependent amplification present challenges for dose selection and clinical translation. Here, we present a mechanistic PKPD model informed by

Indexed as

BacteriophagesDrug Resistance, Multiple, BacterialModels, BiologicalPhage TherapyPseudomonas aeruginosaPseudomonas InfectionsAnimalsHumansMicePseudomonas Phagesbacteriophagesbacteriophage therapycomputational biologymathematical modelingmodel-informed drug developmentphage cocktail optimizationpharmacokinetics pharmacodynamicspredator-prey dynamicsPseudomonas aeruginosaquantitative systems pharmacology

Identifiers

PMID41405200
PMCPMC12710366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.